Your browser doesn't support javascript.
Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice.
Li, Xingxing; Liu, Jingjing; Li, Wenjuan; Peng, Qinhua; Li, Miao; Ying, Zhifang; Zhang, Zelun; Liu, Xinyu; Wu, Xiaohong; Zhao, Danhua; Yang, Lihong; Cao, Shouchun; Huang, Yanqiu; Shi, Leitai; Xu, Hongshan; Wang, Yunpeng; Yue, Guangzhi; Suo, Yue; Nie, Jianhui; Huang, Weijin; Li, Jia; Li, Yuhua.
  • Li X; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Liu J; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Li W; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, China.
  • Peng Q; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Li M; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Ying Z; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Zhang Z; Department of Respiratory Virus Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Liu X; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Wu X; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Zhao D; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Yang L; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Cao S; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Huang Y; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Shi L; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Xu H; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Wang Y; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Yue G; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Suo Y; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Nie J; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Huang W; Department of HIV/AIDS and Sex-transmitted Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.
  • Li J; Department of HIV/AIDS and Sex-transmitted Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.
  • Li Y; Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
Front Immunol ; 14: 1142394, 2023.
Article in English | MEDLINE | ID: covidwho-2268865
ABSTRACT
The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) variants has been associated with the transmission and pathogenicity of COVID-19. Therefore, exploring the optimal immunisation strategy to improve the broad-spectrum cross-protection ability of COVID-19 vaccines is of great significance. Herein, we assessed different heterologous prime-boost strategies with chimpanzee adenovirus vector-based COVID-19 vaccines plus Wuhan-Hu-1 (WH-1) strain (AdW) and Beta variant (AdB) and mRNA-based COVID-19 vaccines plus WH-1 strain (ARW) and Omicron (B.1.1.529) variant (ARO) in 6-week-old female BALB/c mice. AdW and AdB were administered intramuscularly or intranasally, while ARW and ARO were administered intramuscularly. Intranasal or intramuscular vaccination with AdB followed by ARO booster exhibited the highest levels of cross-reactive IgG, pseudovirus-neutralising antibody (PNAb) responses, and angiotensin-converting enzyme-2 (ACE2)-binding inhibition rates against different 2019-nCoV variants among all vaccination groups. Moreover, intranasal AdB vaccination followed by ARO induced higher levels of IgA and neutralising antibody responses against live 2019-nCoV than intramuscular AdB vaccination followed by ARO. A single dose of AdB administered intranasally or intramuscularly induced broader cross-NAb responses than AdW. Th1-biased cellular immune response was induced in all vaccination groups. Intramuscular vaccination-only groups exhibited higher levels of Th1 cytokines than intranasal vaccination-only and intranasal vaccination-containing groups. However, no obvious differences were found in the levels of Th2 cytokines between the control and all vaccination groups. Our findings provide a basis for exploring vaccination strategies against different 2019-nCoV variants to achieve high broad-spectrum immune efficacy.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Female / Humans Language: English Journal: Front Immunol Year: 2023 Document Type: Article Affiliation country: Fimmu.2023.1142394

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Female / Humans Language: English Journal: Front Immunol Year: 2023 Document Type: Article Affiliation country: Fimmu.2023.1142394